A morning symposium on Saturday, June 21, will feature the first report of a phase 3 trial of the oral GLP-1 receptor agonist, orforglipron.
Julio Rosenstock, MD, Senior Scientific Advisor for Velocity Clinical Research, Director of Velocity’s site at Medical City Dallas, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, will present data from ACHIEVE-1 during Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?, which will take place from 8:00–9:30 a.m., in Room W375 A of the McCormick Place Convention Center. The randomized controlled trial is studying orforglipron as monotherapy in drug-naïve type 2 diabetes with inadequate glycemic management.
In topline results, once-daily orforglipron was shown to be superior to placebo in A1C reduction, the study’s primary endpoint. Participants in the orforglipron arm also experienced weight loss, a secondary endpoint. Ongoing studies are evaluating orforglipron for the treatment of type 2 diabetes, for weight management in adults with obesity or overweight and at least one weight-related medical problem, and for the treatment of obstructive sleep apnea and hypertension in adults with obesity.
The symposium also will feature Denise Wootten, PhD, Professor at Monash University, Australia, who will address how better understanding of GLP-1 receptors facilitates improved understanding of where and how small nonpeptide GLP-1 receptor agonists work. She will examine whether all these agents are equally effective.
Tina Vilsbøll, MD, DMSc, Clinical Professor and Head of Clinic at Steno Diabetes Center, Denmark, will discuss the data from currently available phase 2 clinical trials of small nonpeptide GLP-1 receptor agonists and what this research means for the outlook of diabetes treatment.
On-demand access to recorded presentations will be available to registered participants following the conclusion of the 85th Scientific Sessions, from June 25–August 25.
Watch the Scientific Sessions On-Demand after the Meeting
Extend your learning on the latest advances in diabetes research, prevention, and care after the 85th Scientific Sessions conclude. From June 25–August 25, registered participants will have on-demand access to presentations recorded in Chicago via the meeting website.